Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX).

Full DD Report for PCRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: PCRX)

A Migrating Biotech Bear
Biotech Pulse Biotechnology is in a Bear Market. At least the midcap and smallcap segment of it. The S&P Biotechnology Select Index ( XBI ), which is weighted towards the midcap and smallcap companies, has dropped 24% from its high recorded on August 30 to its lowest point past Monda...
Source: SeekingAlpha
Date: November, 06 2018 08:39
Centers for Medicare and Medicaid Services and American Dental Association Establish New Reimbursement for EXPAREL
-- Product-specific C-code for ambulatory surgical center procedures and D-code for dental procedures to take effect January 1, 2019 -- -- Important reimbursement milestone that will expand patient access to non-opioid strategies for postsurgical pain -- PARSIPPANY, N.J., Nov...
Source: GlobeNewswire
Date: November, 02 2018 14:12
Pacira Pharmaceuticals (PCRX) Q3 2018 Results - Earnings Call Transcript
Pacira Pharmaceuticals, Inc. (PCRX) Q3 2018 Earnings Call November 01, 2018 8:30 am ET Executives Susan Mesco - Pacira Pharmaceuticals, Inc. David M. Stack - Pacira Pharmaceuticals, Inc. Richard E. Scranton - Pacira Pharmaceuticals, Inc. Charles A. Reinhart III - Pacira Pharmac...
Source: SeekingAlpha
Date: November, 01 2018 17:38
Pacira Pharmaceuticals beats by $0.22, beats on revenue
Pacira Pharmaceuticals (NASDAQ: PCRX ): Q3 Non-GAAP EPS of $0.31 beats by $0.22 ; GAAP EPS of -$0.02 beats by $0.08 . More news on: Pacira Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 01 2018 08:02
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results
-- EXPAREL® net product sales of $82.2 million up 23% over prior year third quarter -- -- Full-year EXPAREL net product sales guidance increased to $325 to $330 million -- -- Conference Call Today at 8:30 a.m. ET -- PARSIPPANY, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Pacira Ph...
Source: GlobeNewswire
Date: November, 01 2018 08:00
Notable earnings before Thursday's open
AAON , AAWW , ABMD , AGIO , ALE , AMAG , AMCX , AME , AMRN , ARES , AROC , ARW , AVP , AYR , BCE , BID , BLL , BMCH , BSIG , CBRE , CCOI , CEIX , CHD , CHSP , CI , CJ , CNQ , CNSL , CWT , D , DM , DNOW , DWDP , EEX , EGRX , EPAM , EXC , EXLS , FLWS , F...
Source: SeekingAlpha
Date: October, 31 2018 17:30
Aetna Offers Expanded Coverage for EXPAREL® in Select Ambulatory Surgical Centers
Aetna will reimburse for the use of EXPAREL in ambulatory surgical centers in Florida and New Jersey as part of a pilot program       PARSIPPANY, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Aetna has announced that they will reimburse select ambulatory surgical ce...
Source: GlobeNewswire
Date: October, 30 2018 07:30
Pacira to Report Third Quarter 2018 Financial Results on Thursday November 1, 2018
PARSIPPANY, N.J., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday, November 1, 2018. Following the release, the company will host a live confe...
Source: GlobeNewswire
Date: October, 25 2018 07:30
Today's Research Reports on Trending Tickers: Pacira Pharmaceuticals and OPKO Health
NEW YORK, NY / ACCESSWIRE / September 20, 2018 / Wall Street posted mixed results on Wednesday as tech shares weakened and trade tensions continued to rise. The Dow Jones Industrial Average gained 0.61 percent to close at 26,405.76, while the S&P 500 Index hiked 0.13 percent to close at ...
Source: ACCESSWIRE IA
Date: September, 20 2018 08:00
Daily Insider Ratings Round Up 8/30/18
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: September, 03 2018 03:42

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1446.7047.3547.6546.25517,507
2018-05-1434.7534.8035.8534.50512,528
2018-05-1134.4534.5034.7533.60440,306
2018-05-1034.6034.3535.1034.05509,978
2018-05-0932.8534.3034.4531.70839,834

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0722,984127,81817.9818Cover
2018-12-0624,133113,25821.3080Cover
2018-12-0443,23493,92146.0323Short
2018-12-0317,44483,56720.8743Cover
2018-11-3022,54297,99923.0023Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PCRX.


About Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX)

Logo for Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: PCRX)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 02 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: July, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: June, 15 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 16 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 29 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 28 2018

       

       


      Daily Technical Chart for (NASDAQ: PCRX)

      Daily Technical Chart for (NASDAQ: PCRX)


      Stay tuned for daily updates and more on (NASDAQ: PCRX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: PCRX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PCRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PCRX and does not buy, sell, or trade any shares of PCRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/